Evidence Paper Review

 Quick Explanation Copied

 Long Explanation

Core Findings and Evidence Quality

All authors are Bayer AG (Berlin) employees, funded by Bayer AG; no conflicts declared. Using a 384-well high-content Aldefluor assay (robust Z′ = 0.35), they screened 1,108 bioactive/FDA-approved compounds in SUM149 breast cancer cells, with DEAB controls and a 6-SD intensity cutoff. Ten hits reduced ALDH-high cells; five were excluded as false positives that directly inhibited ALDH within 2 h and washed out reversibly High-content CSC screen with false-positive filtering. Critical self-correction: the authors demonstrate ALDH activity itself is dispensable for CSC maintenance (DEAB fails to reduce tumorsphere formation), so the screen marker is a readout, not a target.

Validation includes: ALDH-high sorted cells showing greater tumorsphere formation and radiation resistance; Wnt inhibition (LGK-974, IWR-1, WIKI4) plus siRNA confirming Wnt dependence; three PDE5 inhibitors and PDE5A siRNA reducing ALDH-high cells and tumorsphere formation; 8-pCPT-cGMP mimicking the effect; PKG inhibition (KT5823) phenocopying rather than reversing it; and PKA inhibition (H-89) rescuing CSC loss cGMP-to-PKA mechanism with H-89 rescue. Notably, MY5445 reduced ALDH-high cells (~90% at IC50 3.76 µM) but TFC reduction data show inconsistencies with the abstract's claims of parallel CSC elimination for other hits.

Bars report Table 1 IC50 values; labels show TFC reduction at 10 µM (n ≥ 3, SD). SB 203580 TFC label corresponds to its −24.2% (p<0.05) value.

Critical Limitations and Blind Spots

• Mechanistic gap: The cGMP→cAMP→PKA link is inferred, not demonstrated; PDE1/PDE3 inhibitors failed to replicate PDE5 effects, and direct cAMP measurement or CREB phosphorylation data are absent. H-89 has known off-targets beyond PKA.
• Model dependence: Nearly all mechanistic work is in SUM149; ALDH as a CSC marker is not universal (the authors cite prostate ALDH counterexamples). Only single-line validation in HCT116 and H358.
• No in vivo or patient-derived data: The authors themselves acknowledge that 2D cell lines are limited CSC models and fresh patient cells or animal models are required Authors.
• Translation context: Independent in vitro work shows sildenafil potentiates chemotherapy in pediatric CNS tumor cells via a distinct NO/cGMP mechanism, supporting broader PDE5-inhibitor anticancer plausibility but also revealing that mechanisms differ by tumor type PDE5 inhibitors potentiate medulloblastoma chemotherapy, while clinical safety concerns (e.g., melanoma-risk debate) remain unresolved.

What would falsify the central claim: failure of PDE5A knockout (not just siRNA) to reduce ALDH-high cells in multiple lines; demonstration that H-89 rescues via off-target effects; absence of CSC loss with direct cAMP/PKA activation in patient-derived organoids.

 BGPT Paper Review

Study Novelty

First small-molecule screen for CSC maintenance using high-content single-cell Aldefluor analysis; the cGMP→cAMP→PKA (non-PKG) mechanism for PDE5 in CSCs was novel, though PDE5's role in prostate CSCs was already published (Liu et al. 2016).

Scientific Quality

Rigorous assay controls (DEAB, Z′ factor, false-positive triage, siRNA concordance, wash-out experiments) but pure in vitro, single dominant cell line, pharmacology with known off-target inhibitors (H-89, KT5823), and no cAMP level measurements. Industry funding with all authors employed by Bayer AG; declared no conflict of interest, which is hard to fully disentangle from sponsor interest in PDE5 assets.

Study Generality

Validation across breast, colon, and lung lines suggests broad CSC relevance, but the ALDH-high marker is tumor-type dependent and the mechanism was tested almost entirely in one line.

Study Usefulness

Repurposing clinically approved PDE5 inhibitors (sildenafil, vardenafil) is immediately actionable; the assay methodology and false-positive filtering approach are transferable to other CSC drug screens.

Study Reproducibility

Detailed methods, IC50s with SDs, n ≥ 3, and supplementary tables provided; however, exact cell passages, raw data depositions, and full siRNA sequences (partially garbled in the published SI) limit independent replication.

Explanatory Depth

Good pharmacological epistasis logic (cGMP analog, PKG inhibitor, PKA rescue), but the key mechanistic bridge (which PDE mediates cAMP accumulation) remains explicitly unresolved; no direct second-messenger quantification.